Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Insitro","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$2,100.0 million","upfrontCash":"$50.0 million","newsHeadline":"Insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by Insitro

    Menu

    Insitro

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Insitro

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal ...

              Details:

              Insitro will apply its proprietary platform, the insitro Human (ISH) platform, to create induced pluripotent stem cell (iPSC) derived disease models for ALS and FTD. BMS will be responsible for clinical development and regulatory submissions and commercialization activities.

              Lead Product(s): Undisclosed

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Bristol Myers Squibb

              Deal Size: $2,100.0 million Upfront Cash: $50.0 million

              Deal Type: Collaboration October 28, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY